Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Audrey Simonaggio1, Aurélien Marabelle2

  • 1Gustave Roussy, Université Paris-Saclay, département d'innovation thérapeutique et d'essais précoces, Villejuif, F-94805, France.

Bulletin Du Cancer
|January 1, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.

Journal for immunotherapy of cancer·2026
Same author

Cytokines released by human tumors are independent from cancer histotype.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Future approaches to immune-based biomarkers.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Predicting survival of patients treated with antibody-drug conjugates in early-phase clinical trials using AI-quantified 3D body composition on CT scans.

Frontiers in oncology·2026
Same author

Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Nature·2026

New immunotherapies beyond immune checkpoint inhibitors are crucial for cancer patients who do not respond to current treatments. These alternative therapies target various immune cells, offering new hope for durable tumor responses and improved survival.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapeutics

Background:

  • Immune checkpoint inhibitors (ICIs) like PD-1, PD-L1, and CTLA-4 antibodies have transformed cancer treatment, showing broad activity across many cancer types.
  • Despite ICI success, a significant portion of patients exhibit resistance, necessitating the development of novel immunotherapeutic strategies.
  • Durable responses and improved overall survival are key benefits observed with current immunotherapies.

Purpose of the Study:

  • To review recent advancements in alternative immunotherapies for cancer treatment.
  • To explore novel strategies beyond established immune checkpoint blockade.
  • To summarize emerging therapies targeting both T-cells and innate immune cells.

Main Methods:

  • Review of clinical trials and recent literature on novel immunotherapies.
Keywords:
CancerImmunotherapyImmunothérapie

Related Experiment Videos

  • Analysis of therapies including small molecules, vaccines, cytokines, viruses, and cellular therapies.
  • Focus on therapies targeting a broader range of immune cells, including innate immunity.

    • Main Results:

    • Numerous novel immunotherapies are in clinical development, expanding treatment options.
    • These alternative therapies encompass diverse mechanisms beyond immune checkpoint modulation.
    • Emerging treatments are designed to overcome resistance to monotherapies and broaden efficacy.

    Conclusions:

    • Alternative immunotherapies are essential to address unmet needs in patients resistant to current treatments.
    • The development pipeline includes a wide array of agents targeting diverse immune pathways.
    • Future cancer treatment will likely involve a combination of strategies to enhance anti-tumor immunity.